Posters
View PosterIdentifying Predictive Plasma Proteomic Biomarkers for Clinical Response to AXA1125, an Endogenous Metabolic Modulator (EMM) Composition Being Developed for the Treatment of NAFLD/NASH
Heping Wang, Matthew Russell, Joel Pradines, Cerasela Albei, and Karim Azer
American Association for the Study of Liver Diseases (AASLD) Liver Meeting | November 2022
INTRODUCTION Proteomics and metabolomics data represent opportunities to identify stable and dynamic biomarkers that are measurable in biological fluids. In nonalcoholic steatohepatitis (NASH), these biomarkers are being explored for classifying disease, monitoring disease progression, and assessing treatment response, using signatures representing different components of disease biologies (steatosis, inflammation, ballooning, fibrosis). AXA1125, a novel endogenous metabolic…